New drug aims to shrink hard-to-treat HER2 cancers
NCT ID NCT06031584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BL-M07D1 in people with advanced HER2-positive or HER2-low urinary and digestive tract cancers. The first part finds a safe dose; the second part checks if the drug can shrink tumors. About 42 adults aged 18–75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE URINARY TRACT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact